Dennis Mulroy Sells 3,363 Shares of AnaptysBio (NASDAQ:ANAB) Stock

AnaptysBio, Inc. (NASDAQ:ANAB) CFO Dennis Mulroy sold 3,363 shares of the firm’s stock in a transaction dated Monday, January 5th. The shares were sold at an average price of $43.26, for a total transaction of $145,483.38. Following the completion of the transaction, the chief financial officer directly owned 14,330 shares in the company, valued at $619,915.80. This represents a 19.01% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link.

Dennis Mulroy also recently made the following trade(s):

• On Monday, December 22nd, Dennis Mulroy sold 10,000 shares of AnaptysBio stock. The stock was sold at an average price of $50.00, for a total value of $500,000.00.
• On Tuesday, December 16th, Dennis Mulroy sold 15,725 shares of AnaptysBio stock. The shares were sold at an average price of $44.85, for a total value of $705,266.25.

AnaptysBio Price Performance

NASDAQ ANAB opened at $45.21 on Thursday. The stock’s 50 day simple moving average is $42.31 and its 200-day simple moving average is $31.22. The company has a market cap of $1.25 billion, a PE ratio of -16.03 and a beta of 0.32. AnaptysBio, Inc. has a 1-year low of $12.21 and a 1-year high of $52.47.

AnaptysBio (NASDAQ:ANAB) last posted its quarterly earnings data on Tuesday, November 4th. The biotechnology company reported $0.52 EPS for the quarter, beating the consensus estimate of ($1.06) by $1.58. The firm had revenue of $76.32 million during the quarter, compared to the consensus estimate of $15.83 million. AnaptysBio had a negative return on equity of 1,101.24% and a negative net margin of 49.94%. On average, equities research analysts anticipate that AnaptysBio, Inc. will post -6.08 EPS for the current fiscal year.

AnaptysBio announced that its board has initiated a share buyback program on Friday, November 21st that allows the company to buyback $100.00 million in shares. This buyback authorization allows the biotechnology company to reacquire up to 9.6% of its shares through open market purchases. Shares buyback programs are usually a sign that the company’s leadership believes its shares are undervalued.

Key AnaptysBio News

Here are the key news stories impacting AnaptysBio this week:

• Positive Sentiment: Strong quarter: AnaptysBio reported an EPS beat and materially higher revenue versus consensus in its most recent quarter — a result that underpins the stock rerating and analyst optimism. Read More.
• Positive Sentiment: Share repurchase: The board authorized up to $100 million in buybacks (~9.6% of shares), which reduces float and signals management confidence — typically supportive for the stock. Read More.
• Positive Sentiment: Analyst support: Multiple firms maintain Buy/Overweight ratings and the consensus target remains above the current price, helping attract demand from institutional and retail investors. Read More.
• Neutral Sentiment: Event catalyst: CEO Daniel Faga will present at the J.P. Morgan Healthcare Conference on Jan. 13 — a common venue for new data, partnership or strategy updates, but movement depends on what is announced. Read More.
• Neutral Sentiment: Institutional flows: Several funds have increased or initiated positions recently, which can provide steady demand but also raises the possibility of larger block trades if they rebalance. Read More.
• Negative Sentiment: Insider selling: Multiple insiders, including CEO Daniel Faga (15,309 shares), CFO Dennis Mulroy and others, filed Form 4s disclosing sales at about $43.26 on Jan. 5 — a move that can be read negatively by the market even if for diversification or tax reasons. Read More.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on ANAB shares. Guggenheim reaffirmed a “buy” rating on shares of AnaptysBio in a research note on Thursday, December 18th. Wells Fargo & Company boosted their target price on AnaptysBio from $51.00 to $81.00 and gave the stock an “overweight” rating in a report on Wednesday, November 5th. Wedbush reaffirmed an “outperform” rating and issued a $50.00 price target on shares of AnaptysBio in a report on Monday, November 24th. Wall Street Zen raised AnaptysBio from a “buy” rating to a “strong-buy” rating in a research note on Sunday, November 16th. Finally, Barclays dropped their target price on AnaptysBio from $70.00 to $55.00 and set an “overweight” rating for the company in a report on Wednesday, December 17th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $60.40.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Larson Financial Group LLC raised its position in AnaptysBio by 54.6% in the third quarter. Larson Financial Group LLC now owns 1,340 shares of the biotechnology company’s stock valued at $41,000 after purchasing an additional 473 shares during the period. Bessemer Group Inc. grew its holdings in shares of AnaptysBio by 950.0% during the 3rd quarter. Bessemer Group Inc. now owns 1,428 shares of the biotechnology company’s stock worth $44,000 after purchasing an additional 1,292 shares during the period. Tower Research Capital LLC TRC increased its position in shares of AnaptysBio by 175.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 2,164 shares of the biotechnology company’s stock worth $48,000 after purchasing an additional 1,377 shares during the last quarter. Osaic Holdings Inc. raised its holdings in AnaptysBio by 11,630.0% in the 2nd quarter. Osaic Holdings Inc. now owns 2,346 shares of the biotechnology company’s stock valued at $52,000 after buying an additional 2,326 shares during the period. Finally, Covestor Ltd lifted its position in AnaptysBio by 131,540.0% in the third quarter. Covestor Ltd now owns 6,582 shares of the biotechnology company’s stock valued at $201,000 after buying an additional 6,577 shares during the last quarter.

AnaptysBio Company Profile

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.